Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been assigned an average rating of “Hold” from the twelve research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $5.75.

A number of research analysts have weighed in on MRVI shares. Robert W. Baird decreased their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, May 13th. Royal Bank Of Canada decreased their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Tuesday, August 12th. Finally, Craig Hallum decreased their price objective on shares of Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MRVI. 12 West Capital Management LP raised its position in shares of Maravai LifeSciences by 8.0% during the 1st quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company’s stock worth $27,672,000 after purchasing an additional 930,000 shares during the last quarter. Alyeska Investment Group L.P. raised its position in shares of Maravai LifeSciences by 145.8% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company’s stock worth $29,045,000 after purchasing an additional 3,161,072 shares during the last quarter. Mirabella Financial Services LLP raised its position in shares of Maravai LifeSciences by 0.3% during the 2nd quarter. Mirabella Financial Services LLP now owns 3,750,000 shares of the company’s stock worth $9,038,000 after purchasing an additional 10,049 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Maravai LifeSciences by 1.8% during the 4th quarter. Ameriprise Financial Inc. now owns 3,611,625 shares of the company’s stock worth $19,683,000 after purchasing an additional 62,123 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Maravai LifeSciences by 12.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,984,045 shares of the company’s stock worth $7,193,000 after purchasing an additional 319,679 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Trading Up 2.5%

Shares of Maravai LifeSciences stock opened at $2.45 on Friday. The firm has a 50-day simple moving average of $2.45 and a two-hundred day simple moving average of $2.50. The company has a market cap of $623.92 million, a P/E ratio of -1.80 and a beta of 0.28. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $9.60. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.49 and a current ratio of 5.16.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.